Director WAGENHEIM PHILIP sold 65,000 shares (65.0K shares) at blended $20.55 for $1,335,626.00; holds 341.1K shares post-transaction
Director Philip Wagenheim executed 2 separate sales totaling 65,000 shares for $1,335,626.00 on March 20 and 23, 2026, reducing his stake by 16.0% from 406,147 to 341,147 shares. The sales occurred at prices ($20.47 and $20.65) near current market levels ($20.75 currently, -23.1% from 52-week high of $26.97), suggesting execution without apparent timing advantage relative to recent trading range. Immunome remains unprofitable with net income of $-57,457,000.00 in the most recent period and annual revenue decline of -23.2% year-over-year, creating a backdrop of operational headwinds. The magnitude of the sale—representing a material reduction in insider holdings—warrants attention given the company's negative earnings trajectory, though the sale price's proximity to current market levels and the director's retention of substantial remaining shares provide some context.